What's new and not so new on the antimicrobial horizon?

Clinical Microbiology and Infection

Volumn 14, Issue SUPPL. 6, 2008, Pages 19-29

  French, Gary L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Carbapenem; Ceftobipole; Cephalosporin; Doripenem; Iclaprim

Indexed keywords

CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; CEPHALOSPORIN; DORIPENEM; ICLAPRIM; IMIPENEM; LINEZOLID; MEROPENEM; TRIMETHOPRIM;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; HUMAN; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PENICILLIN RESISTANCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE;

ENTEROCOCCUS FAECALIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; STREPTOCOCCUS PNEUMONIAE;

EID: 56849099664     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02124.x     Document Type: Conference Paper

References (30)

1. Williams RE. Epidemic staphylococci. Lancet 1959; 1: 190-195.
2. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997; 24(suppl 1): S67-S73.
3. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998; 42: 1303-1304.
4. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357: 1179.
5. Finland M, Jones WF Jr, Barnes MW. Occurrence of serious bacterial infections since introduction of antibacterial agents. JAMA 1959; 170: 2188-2197.
6. Wenzel RP. The antibiotic pipeline-challenges, costs, and values. N Engl J Med 2004; 351: 523-526.
7. Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001; 29(4 suppl): N64-N68.
8. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134: 298-314.
9. Cohen ML. Epidemiology of drug resistance: Implications for a post-antimicrobial era. Science 1992; 257: 1050-1055.
10. Kunin CM. Resistance to antimicrobial drugs - a worldwide calamity. Ann Intern Med 1993; 118: 557-561.
11. Neu HC. The crisis in antibiotic resistance. Science 1992; 257: 1064-1073.
12. Livermore DM. The need for new antibiotics. Clin Microbiol Infect. 2004; 10(suppl 4): 1-9.
13. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: A potential serious threat to public health. Lancet Infect Dis 2005; 5: 115-119.
14. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: Implications for the future. Clin Infect Dis 2004; 38: 1279-1286.
15. Metlay JP, Powers JH, Dudley MN, Christiansen K, Finch RG. Antimicrobial drug resistance, regulation, and research. Emerg Infect Dis 2006; 12: 183-190.
16. Wise R. Antimicrobial resistance: Paradox, actions and economics. J Antimicrob Chemother 2006; 57: 1024-1025.
17. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48: 3136-3140.
18. Schmitt-Hoffmann A, Nyman L, Roos B et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 2576-2580.
19. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003; 13: 4217-4221.
20. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002; 50: 915-932.
21. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49: 4210-4219.
22. Zbinden R, Punter V, von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters. Antimicrob Agents Chemother 2002; 46: 871-874.
23. Wootton M, Bowker KE, Holt HA, MacGowan AP. BAL.9141, a new broad-spectrum pyrrolidinone cephalosporin: Activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J Antimicrob Chemother 2002; 49: 535-539.
24. Noel GJ, Strauss RS, Amsler M, Heep R, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008; 55: 37-44.
25. Doripenem: S.4661. Drugs R D. 2003; 4: 363-365.
26. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005; 52: 71-74.
27. Lister PD. Carbapenems in the USA: Focus on doripenem. Expert Rev Anti Infect Ther 2007; 5: 793-809.
28. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003). Clin Microbiol Infect 2005; 11: 974-984.
29. Kohlhoff SA, Sharma R. Iclaprim. Expert Opin Investig Drugs 2007; 16: 1441-1448.
30. Kohlhoff SA, Roblin PM, Reznik T, Hawser S, Islam K, Hammerschlag MR. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C..pneumoniae. Antimicrob Agents Chemother 2004; 48: 1885-1886.